ClinicalTrials.gg
CompletedNCT07918261Updated Nov 5, 2026

Evaluation of Fisetin to Reduce Systemic Senescence

A Phase 1/2 interventional study of Fisetin (daily dosing) and Fisetin (bolus dosing) in Cellular Senescence, sponsored by Steadman Philippon Research Institute. Completed at 1 site in United States. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Steadman Philippon Research Institute · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled May 2023, registered Oct 2026).
Updated Nov 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.

Read the detailed description

This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.

02

Conditions studied

  • Cellular Senescence

Keywords

  • Fisetin
  • Peripheral Blood Mononuclear Cells
  • Cellular Senescence
03

In context

Lead sponsor

Steadman Philippon Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥55 years of age;
  • Capacity to personally give (consent via legally authorized representative will not be accepted);
  • Willing to comply with all study procedures and assessments.

Exclusion criteria

Exclusion Criteria:

  • Within 2 years of signing history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
  • Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
  • Males who do not wish to abstain from sex with women of without use of protection by either party during drug dosing;
  • Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
  • Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
  • Subjects with any of the following drug/medication statuses:

    1. Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
    2. Currently taking Warfarin or related anticoagulants;
    3. Currently taking Lithium;
    4. Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
    5. Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
    6. Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
    7. Taking a within 1 month of signing informed consent;
    8. Currently taking phenytoin or nateglinide;
  • PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
  • Inability to tolerate oral medication;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Fisetin (daily dosing)

    A single Fisetin 100mg capsule will be taken daily for 60 days.

    Drug: Fisetin (daily dosing)

  • Experimental
    Fisetin (bolus dosing)

    Fisetin 100 mg capsules (\~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1\&2, and 31\&32.

    Drug: Fisetin (bolus dosing)

Interventions

  • Oral Fisetin 100mg capsule

    Also known as: Novusetin, 7,3',4'-flavon-3-ol, 3,3',4',7-tetrahydroxyflavone

  • Oral Fisetin 100mg capsule, dosed at 20 mg/kg

    Also known as: Novusetin, 7,3',4'-flavon-3-ol, 3,3',4',7-tetrahydroxyflavone

06

What researchers measure

Primary outcomes

  1. Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)

    Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

    Time frame: Baseline, Visit 4 (45 days)

Secondary outcomes

  1. Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)

    Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

    Time frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)

  2. Change from baseline in senescence-related serum biomarkers

    Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma.

    Time frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

  3. Number of participants experiencing one or more treatment-emergent adverse events

    Number of participants experiencing one or more treatment-emergent adverse events

    Time frame: From date of study drug dosing until the end of the study, an average of 2 months

  4. Perturbations in senescent PBMC values

    Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

    Time frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

  5. Perturbations in senescent serum/plasma biomarkers values

    The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA.

    Time frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

07

Study locations

1 site
  • Steadman Philippon Research Institute
    Vail, Colorado 81657, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jan 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 5, 2026
StartActual
May 24, 2023
Primary completionActual
Jan 30, 2024
CompletionActual
Jan 30, 2024
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07918261
Lead sponsor
Steadman Philippon Research Institute
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
May 24, 2023
Primary completion
Jan 30, 2024
Completion
Jan 30, 2024
Last update
Nov 5, 2026

Study contacts

Johnny Huard, PhD
principal investigator · Steadman Philippon Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fisetin

Start the discussion